Aripiprazole: 132.1 (129.5) daysLurasidone: 160.6 (132.5) daysOlanzapine: 151.0 (141.4) daysRisperidone: 147.9 (138.0) daysCariprazine: 174.1 (138.8) days<\/p>\n
In addition, at least half of the patients on OLZ\/SAM stayed on treatment for 280 days or longer vs median durations of 67 to 121 for the comparators. Adherence, defined as a medication possession ratio of 0.80 or higher, also favored OLZ\/SAM, with ORs of 1.33 to 2.53 (all P < .01). The degree of the advantage varied by comparator drug, and the gap was more narrow against some drugs compared with others, the authors highlighted, so the pooled picture should be read alongside the individual comparisons.<\/p>\n
The authors concluded that \u201cmore consistent antipsychotic medication use may translate into meaningful improvements in schizophrenia-associated outcomes.\u201d<\/p>\n
Fewer Acute Care Events5<\/p>\n
In the second poster, the authors sought to answer this question: Were there differences in treatment patterns and acute care events between use of OLZ\/SAM and use of olanzapine alone? The study authors were unaware of previous real-world analysis of their question. For this investigation, Medicaid-insured adults were matched 1:1. For the schizophrenia analysis, there were 807 patients each on OLZ\/SAM and olanzapine alone. For BD-1, 504 patients each, respectively.<\/p>\n
For schizophrenia, 63.1% of patients receiving the combination were adherent compared with 45.0% of those receiving olanzapine alone (OR, 2.09; 95% CI, 1.72-2.54; P < .001). Mean (SD) persistence was 202.9 (144.3) vs 146.8 (140.0) days, respectively, and discontinuation was less common with OLZ\/SAM (61.0% vs 75.8%; OR, 0.50; 95% CI, 0.40-0.61; P < .001). For BD-I, the results trended similarly, with an adherence rate of 57.5% with OLZ\/SAM vs 48.2% with olanzapine (OR, 1.46; 95% CI, 1.14-1.86; P = .003), and discontinuation was lower (66.9% vs 79.2%; OR, 0.53; 95% CI, 0.40-0.71; P < .001). Time on treatment was also longer with OLZ\/SAM: by 38% in schizophrenia and 29% in BD-I.<\/p>\n
Hospital and emergency department (ED) use, which the authors treated as proxies for relapse, again favored OLZ\/SAM. In schizophrenia, 31.9% of patients on OLZ\/SAM had an all-cause inpatient admission vs 46.0% of patients on olanzapine alone (OR, 0.55; 95% CI, 0.45-0.67; P < .001), 28.1% vs 43.0% had a mental health\u2013related admission (OR 0.52; 95% CI, 0.42-0.64; P < .001), and 24.2% vs 35.2% had a schizophrenia-related admission (OR 0.59; 95% CI, 0.47-0.73) (all P < .001). In BD-1, the respective findings were 25.2% vs 36.9% (OR, 0.58; 95% CI, 0.45-0.74), 21.2% vs 33.3% (OR, 0.54; 95% CI, 0.41-0.71), and 16.1% vs 27.0% (OR, 0.52; 95% CI, 0.38-0.70) (all P < .001).<\/p>\n
ED visits were also less likely with OLZ\/SAM in the schizophrenia arm, with an OR of 0.47 (95% CI, 0.38-0.57) for a mental health\u2013related admission, 0.51 (95% CI, 0.41-0.64) for a disease-related admission, and 0.54 (95% CI, 0.44-0.66) for an all-cause admission (all P < .001). In BD-I, the respective ORs were 0.63 (95% CI, 0.48-0.82; P < .001), 0.62 (95% CI, 0.44-0.86; P = .004), and 0.74 (95% CI, 0.58-0.95; P = .019).<\/p>\n
The authors concluded that a \u201csignificantly lower likelihood of disease-related acute care events suggests a lower relapse risk with OLZ\/SAM treatment.\u201d<\/p>\n
References<\/p>\n
Zipursky RB, Agid O, Remington G. Antipsychotic discontinuation in schizophrenia: rational or reckless? Schizophrenia (Heidelb). 2025;11(1):150. doi:10.1038\/s41537-025-00698-8Taylor D. Special feature on antipsychotic discontinuation in schizophrenia. Schizophrenia (Heidelb). 2025;11(1):152. doi:10.1038\/s41537-025-00696-wRead J. The experiences of 585 people when they tried to withdraw from antipsychotic drugs. Addict Behav Rep. 2022;15:100421. doi:10.1016\/j.abrep.2022.100421Cutler AJ, Correll CU, Jain R, et al. Real-world persistence on olanzapine\/samidorphan versus other oral second-generation antipsychotics in patients with schizophrenia. Presented at: AMCP Nexus 2026; October 26-29, 2026; San Diego, CA. Poster 214.Panchmatia HR, Jain R, Hughes AG, Doane MJ, Chepke C, Cutler AJ. Real-world comparison of olanzapine\/samidorphan vs olanzapine: an assessment of treatment patterns and acute care events among patients with schizophrenia or bipolar I disorder. Presented at: AMCP Nexus 2026; October 26-29, 2026; San Diego, CA. Poster 213. <\/p>\n","protected":false},"excerpt":{"rendered":"Aripiprazole: 132.1 (129.5) daysLurasidone: 160.6 (132.5) daysOlanzapine: 151.0 (141.4) daysRisperidone: 147.9 (138.0) daysCariprazine: 174.1 (138.8) days In addition,…\n","protected":false},"author":2,"featured_media":643190,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[134,111,139,69],"class_list":["post-643189","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-new-zealand","tag-newzealand","tag-nz"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/643189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=643189"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/643189\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/643190"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=643189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=643189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=643189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}